BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36645174)

  • 21. Prognostic Significance of the CXCLs and Its Impact on the Immune Microenvironment in Ovarian Cancer.
    Gu C; Xiong X; Liu W
    Dis Markers; 2023; 2023():5223657. PubMed ID: 36798787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a multi-gene-based immune prognostic signature in ovarian Cancer.
    Cao T; Shen H
    J Ovarian Res; 2021 Jan; 14(1):20. PubMed ID: 33509250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
    Shi T; Gao G
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation Analysis of Prognostic Gene Expression, Tumor Microenvironment, and Tumor-Infiltrating Immune Cells in Ovarian Cancer.
    Li Q; Yang Z; Ling X; Ye J; Wu J; Wang Y; Yao C; Zheng J
    Dis Markers; 2023; 2023():9672158. PubMed ID: 37841886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study.
    Gao Y; Chen L; Cai G; Xiong X; Wu Y; Ma D; Li SC; Gao Q
    Oncoimmunology; 2020; 9(1):1760067. PubMed ID: 32391193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer.
    Mao L; Tang Y; Deng MJ; Huang CT; Lan D; Nong WZ; Li L; Wang Q
    J Clin Lab Anal; 2022 Feb; 36(2):e24232. PubMed ID: 34995016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elafin is related to immune infiltration and could predict the poor prognosis in ovarian cancer.
    Lu W; Xie B; Tan G; Dai W; Ren J; Pervaz S; Li K; Li F; Wang Y; Wang M
    Front Endocrinol (Lausanne); 2023; 14():1088944. PubMed ID: 36742380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.
    Zheng P; Li N; Zhan X
    Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.
    Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB
    Front Immunol; 2023; 14():1151109. PubMed ID: 37063862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
    Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
    Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Analysis of Prognosis and Immune Infiltration of Ovarian Cancer Based on Homeobox D Genes.
    Chen B; Gao C; Wang H; Sun J; Han Z
    Comput Math Methods Med; 2022; 2022():3268386. PubMed ID: 36213580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
    Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
    Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics of Ovarian Cancer Immune Cell Invasion and Bioinformatics to Predict the Effect of Immunotherapy.
    Yan L; Fan E; Tan B
    Horm Metab Res; 2024 Mar; 56(3):197-205. PubMed ID: 38242159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response.
    Chen J; Chen S; Dai X; Ma L; Chen Y; Bian W; Sun Y
    Front Immunol; 2022; 13():1007326. PubMed ID: 36189254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer.
    Liu Q; Yang X; Yin Y; Zhang H; Yin F; Guo P; Zhang X; Sun C; Li S; Han Y; Yang Z
    Oxid Med Cell Longev; 2022; 2022():6575534. PubMed ID: 36561981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Machine Learning Developed a Programmed Cell Death Signature for Predicting Prognosis, Ecosystem, and Drug Sensitivity in Ovarian Cancer.
    Wang L; Chen X; Song L; Zou H
    Anal Cell Pathol (Amst); 2023; 2023():7365503. PubMed ID: 37868825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of the prognostic value of LACTB2 and its correlation with immune infiltrates in ovarian cancer by integrated bioinformatics analyses.
    Cao W; Wang C; Zhang Y; Yang J; Luo X; Zhao Y; Wu M; Cheng S; Wang Y
    Eur J Med Res; 2024 Mar; 29(1):166. PubMed ID: 38475882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated analysis of tumor-associated macrophage infiltration and prognosis in ovarian cancer.
    Tan Q; Liu H; Xu J; Mo Y; Dai F
    Aging (Albany NY); 2021 Oct; 13(19):23210-23232. PubMed ID: 34633990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.